Interim Report
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".
Company
Profile
The Company was established in January 2003 and listed on The Stock Exchange of Hong Kong Limited (stock code: 01099. HK) in September 2009, is a core subsidiary of China National Pharmaceutical Group Co., Ltd.
and the largest wholesaler and retailer of pharmaceutical and medical devices and healthcare products, and a leading supply-chain
service provider in the PRC.
The Group is mainly engaged in pharmaceutical and medical devices distribution business. Leveraging on its nationwide distribution and delivery network, the Group provides comprehensive distribution, delivery and other value-added services to domestic and foreign manufacturers and suppliers of pharmaceutical products, medical devices and consumables and other healthcare products, and also to downstream customers including hospitals, other distributors, retail drug stores and primary health services institutions.
Meanwhile, the Group manages its network of retail drug stores chain in major cities of China via direct operations and franchises to sell pharmaceutical and healthcare products to end customers. It has become a leader in China's pharmaceutical retail industry.
Besides, the Group is also engaged in the production and sale of pharmaceutical products, chemical reagents and laboratory supplies, and actively engaged in the innovation of pharmaceutical, medical services and other health-related industries, to explore the synergistic development of its diversified businesses.
Taking advantage of its superior economies of scale, customer resources, network platforms and brand position, the Group will fully leverage on China's pharmaceutical and healthcare market, which shows steady and healthy growth, and capture opportunities arising from healthcare reform to further consolidate and enhance its market leadership, actively striving to become a pharmaceutical and healthcare service provider with international competitiveness.
SINOPHARM GROUP CO. LTD. | 1 |
INTERIM REPORT 2021
Corporate
Mission
All for Health Health for All
Contents
Corporate
Vision
Becoming a distinguished
(technological and innovative)
global pharmaceutical and healthcare service provider
1 Company Profile
3 Corporate Information
5 Definitions
7 Management Discussion and Analysis
23 Biographies of Directors, Supervisors and Senior Management
34 Other Information
- Independent Review Report
- Interim Condensed Consolidated Statement of Profit or Loss
- Interim Condensed Consolidated Statement of Comprehensive Income
- Interim Condensed Consolidated Statement of Financial Position
- Interim Condensed Consolidated Statement of Changes in Equity
- Interim Condensed Consolidated Statement of Cash Flows
50 Notes to the Interim Condensed Consolidated Financial Information
2 SINOPHARM GROUP CO. LTD.
INTERIM REPORT 2021
Corporate Information
As at the date of this report
Directors | Strategy and Investment Committee |
Mr. Yu Qingming (Executive Director and Chairman) | Mr. Yu Qingming (Chairman) |
Mr. Liu Yong (Executive Director and President) | Mr. Liu Yong |
Mr. Chen Qiyu (Non-executive Director and Vice Chairman) | Mr. Chen Qiyu |
Mr. Hu Jianwei (Non-executive Director) | Mr. Hu Jianwei |
Mr. Ma Ping (Non-executive Director) | Mr. Ma Ping |
Mr. Deng Jindong (Non-executive Director) | Mr. Deng Jindong |
Mr. Wen Deyong (Non-executive Director) | Mr. Wen Deyong |
Mr. Li Dongjiu (Non-executive Director) | Mr. Li Dongjiu |
Ms. Feng Rongli (Non-executive Director) | Mr. Chen Fangruo |
Mr. Zhuo Fumin (Independent Non-executive Director) | Mr. Li Peiyu |
Mr. Chen Fangruo (Independent Non-executive Director) | |
Mr. Li Peiyu (Independent Non-executive Director) | Audit Committee |
Mr. Wu Tak Lung (Independent Non-executive Director) | |
Mr. Yu Weifeng (Independent Non-executive Director) | Mr. Wu Tak Lung (Chairman) |
Supervisors | Mr. Deng Jindong |
Mr. Li Dongjiu | |
Mr. Zhuo Fumin | |
Ms. Guan Xiaohui (Chief Supervisor) | Mr. Li Peiyu |
Mr. Liu Zhengdong | |
Mr. Zhang Hongyu | Remuneration Committee |
Ms. Lu Haiqing | |
Joint Company Secretaries | Mr. Li Peiyu (Chairman) |
Mr. Deng Jindong | |
Ms. Feng Rongli | |
Mr. Wu Yijian | Mr. Wu Tak Lung |
Mr. Chan Sing Yuen Roy | Mr. Yu Weifeng |
Nomination Committee | |
Mr. Yu Qingming (Chairman) | |
Mr. Hu Jianwei | |
Ms. Feng Rongli | |
Mr. Zhuo Fumin | |
Mr. Chen Fangruo | |
Mr. Wu Tak Lung | |
Mr. Yu Weifeng |
SINOPHARM GROUP CO. LTD. | 3 |
INTERIM REPORT 2021
Corporate Information
As at the date of this report
Legal and Compliance and
Environmental, Social and
Governance Committee
Mr. Yu Weifeng (Chairman)
Mr. Yu Qingming
Mr. Liu Yong
Authorized Representatives
Mr. Yu Qingming
Mr. Wu Yijian
Legal Advisers
As to Hong Kong and United States laws:
DLA Piper UK LLP
As to PRC law:
Beijing Zhonglun (Shanghai) Law Firm
Shanghai Boss & Young Attorneys at Law
Auditor
International auditor:
Ernst & Young
Registered PIE auditor
Domestic auditor:
Ernst & Young Hua Ming LLP
Principal Place of Business in Hong Kong
Room 1601,
Emperor Group Center,
288 Hennessy Road,
Wanchai, Hong Kong
Principal Place of Business and Headquarters in the PRC
Sinopharm Group Building,
No. 385, East Longhua Road, Huangpu District,
Shanghai 200023, the PRC
4 SINOPHARM GROUP CO. LTD.
Registered Office in the PRC
1st Floor, No.385, East Longhua Road, Huangpu District, Shanghai 200023, the PRC
Company's Website
www.sinopharmgroup.com.cn
H Share Registrar
Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor,
Hopewell Centre
183 Queen's Road East
Wanchai, Hong Kong
Stock Code
01099
Principal Banks
Bank of Communications Co., Ltd., Shanghai Branch China Merchants Bank Co., Ltd., Shanghai Branch Bank of China Limited, Shanghai Branch
China Minsheng Banking Corp., Ltd., Shanghai Branch Industrial and Commercial Bank of China Limited,
Shanghai Branch
Agricultural Bank of China Co., Ltd., Shanghai Branch China Construction Bank Co., Ltd., Shanghai Branch
Office of Board of Directors
Tel:(+86 21)2305 2666
Email:ir@sinopharm.com
INTERIM REPORT 2021
Attachments
- Original document
- Permalink
Disclaimer
Sinopharm Group Co. Ltd. published this content on 11 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 September 2021 07:31:07 UTC.